Table 2.
Mean monthly costs in cases and controls, net and relative differences, and DID over the first 15 months of follow-up
| Mean monthly costs, US$ | Net difference, US$ | Relative difference (%) | ||
| Cases | Controls | |||
| Prepandemic costs | ||||
| Not hospitalised during acute COVID-19, N=626 851 | 84.5 | 85.6 | −1.1 | −1.3 |
| Hospitalised during acute COVID-19, N=16 017 pairs | 268.2 | 203.6 | 64.6 | 31.7 |
| Total, N=642 868 | 89.0 | 88.4 | 0.6 | 0.7 |
| Individual post-COVID-19 costs: months 1–15 of follow-up | ||||
| Not hospitalised during acute COVID-19, N=626 851 | 100.9 | 97.0 | 3.9 | 4.0 |
| Hospitalised during acute COVID-19, N=16 017 pairs | 382.9 | 226.7 | 156.2 | 68.9 |
| Total, N=642 868 | 108.8 | 100.6 | 8.2 | 8.2 |
| DID: post-COVID-19 excess costs, after the subtraction of pre-COVID-19 differences (relative difference compared with post-COVID-19 costs in controls) | ||||
| Not hospitalised during acute COVID-19, N=626 851 | 5.0 | 5.2 | ||
| Hospitalised during acute COVID-19, N=16 017 pairs | 91.6 | 40.4 | ||
| Total, N=642 868 | 7.6 | 7.6 | ||
DID, difference in difference.